Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses.
Rift Valley fever virus (RVFV) is a highly pathogenic member of the family Bunyaviridae that needs to be handled under biosafety level (BSL) 3 conditions. Here, we describe reverse genetics systems to measure RVFV polymerase activity in mammalian cells and to generate virus-like particles (VLPs). Recombinant polymerase (L) and nucleocapsid protein (N), expressed together with a minireplicon RNA, formed transcriptionally active nucleocapsids. These could be packaged into VLPs by additional expression of viral glycoproteins. The VLPs resembled authentic virus particles and were able to infect new cells. After infection, VLP-associated nucleocapsids autonomously performed primary transcription, and co-expression of L and N in VLP-infected cells allowed subsequent replication and secondary transcription. Bunyaviruses are potently inhibited by a human interferon-induced protein, MxA. However, the affected step in the infection cycle is not entirely characterized. Using the VLP system, we demonstrate that MxA inhibits both primary and secondary transcriptions of RVFV. A set of infection assays distinguishing between virus attachment, entry, and subsequent RNA synthesis confirmed that MxA is able to target immediate early RNA synthesis of incoming RVFV particles. Thus, our reverse genetics systems are useful for dissecting individual steps of RVFV infection under non-BSL3 conditions.
Habjan
Matthias
M
Department of Virology, University of Freiburg, D-79008 Freiburg, Germany.
Penski
Nicola
N
Wagner
Valentina
V
Spiegel
Martin
M
Overby
Anna K
AK
Kochs
Georg
G
Huiskonen
Juha T
JT
Weber
Friedemann
F
D000818:Animals; D000911:Antibodies, Monoclonal; D000998:Antiviral Agents / Q000378:metabolism; D002460:Cell Line; D002522:Chlorocebus aethiops; D019204:GTP-Binding Proteins / Q000494:pharmacology; D015967:Gene Expression Regulation, Viral / Q000187:drug effects; D006801:Humans; D051379:Mice; D064547:Myxovirus Resistance Proteins; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism*; D012296:Rift Valley fever virus / Q000235:genetics* / Q000378:metabolism*; D014709:Vero Cells; D014771:Virion / Q000378:metabolism*; D014773:Virology / Q000379:methods
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D011994:Recombinant Proteins; D019204:GTP-Binding Proteins